Table 2.
Effect of antidiabetic drugs on lifespan in mice and rats.
| Strain | Sex | Treatment | No. of animals | Life span, days | References | ||
|---|---|---|---|---|---|---|---|
| Mean | Last 10% of survivors | Maximum | |||||
| Mice | |||||||
| C3H/Sn | Female | Control | 30 | 450 ± 23.4 | 631 ± 11.4 | 643 | 133 |
| Phenformin | 24 | 545 ± 39.2 (+21.1%) | 810 ± 0 * (+28.4%) | 810 (+26%) | |||
| FVB/N | Female | Control | 34 | 264 ± 3.5 | 297 ± 7.3 | 311 | 134 |
| Metformin | 32 | 285 ± 5.2 (+8.0%) | 336 ± 2.7 (+13.1%)* | 340 (+16.2%) | |||
| FVB/N | Female | Control | 15 | 285 ± 12 | 396 ± 0 | 396 | 135 |
| Metformin | 20 | 304 ± 10 | 352 ± 7 | 359 | |||
| SHR | Female | Control | 50 | 388 ± 29.2 | 727 ± 22.5 | 814 | 136 |
| Metformin | 50 | 535 ± 31.9* (+37.9%) | 878 ± 6.6* (+20.8%) | 898 (+10.3%) | |||
| SHR | Female | Control | 119 | 511 ± 20.3 | 881 ± 12.8 | 941 | 137 |
| Metformin | 51 | 583 ± 26.7 (+14.1%) | 897 ± 27.4* | 972 | |||
| 129/Sv | Male | Control | 41 | 662 ± 27.7 | 951 ± 32.3 | 1029 | 138 |
| Metformin | 46 | 573 ± 26.5 (-13.4%)* | 931 ± 30.4 | 1044 | |||
| 129/Sv | Female | Control | 47 | 706 ± 20.8 | 910 ± 8.9 | 930 | |
| Metformin | 48 | 742 ± 16.3 (+5.1%) | 913 ± 19.2 | 966 (+3.9%) | |||
| Rats | |||||||
| LIO | Female | Control | 41 | 652 ± 27.3 | 885 ± 11.3 | 919 | 139 |
| Phenformin | 44 | 652 ± 28.7 | 974± 16.2** (+10.1%) | 1009 (+9.8%) | |||
| Female | Control | 74 | 687 ± 19.2 | 925 ± 22.5 | 1054 | 140 | |
| Buformin | 42 | 737 ± 26.4 (+7.3%) | 1036± 38.9* (+12%) | 1112 (+5.5%) | |||
| Fischer-344 | Male | Control | 31 | 796 ± 170 | 1039 ± 29.6 | 1065 | 141 |
| Metformin | 40 | 815 ± 186 | 1061 ± 2.5 | 1062 | |||
The difference with control is significant:
*
- p < 0.05;
**
p < 0.01 (Student's test)